Company intelligence / Profile preview

Spire

Waltham, Massachusetts, United States

Ownership: Private
Employees: ~65
Development stage: Other

Overview

Interim Phase 1 data for SPY001 showed promising results for IBD. Phase 1 trials for SPY002 and SPY003 underway with readouts expected in 2025. Phase 2 platform trial initiating mid-2025 for ulcerative colitis and rheumatoid arthritis, with monotherapy and combination therapy readouts in 2026.

Therapeutic areas: ImmunologyGastroenterology
Modalities: Monoclonal antibodyAntibody-drug conjugate
Industry: Biotech

Partnerships

Investor syndicate includes Fairmount Funds Management

Beyond the preview

Go deeper on Spire.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spire.

Explore the full profile